Click a link below to view the mailing archive as if it had been sent to you.
| 2022-11-30 12:15 | | Large pharmas probe takeover of Horizon Therapeutics and more... |
| 2022-11-30 00:15 | | Nestlé to Sell Off Peanut Allergy Treatment, Not the Blockbuster They Hoped and more... |
| 2022-11-29 12:15 | | AstraZeneca Deepens Cancer Cell Therapy Portfolio with Neogene Buyout and more... |
| 2022-11-29 00:15 | | Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal and more... |
| 2022-11-28 12:15 | | Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability and more... |
| 2022-11-28 00:15 | | FDA pushes back Gamida Cell’s PDUFA date by three months and more... |
| 2022-11-27 00:15 | | Hemispherian raises the first tranche of a Series A to fund the development of its novel cancer therapeutics and more... |
| 2022-11-23 12:15 | | Racing rising resistance, Novartis marches malaria therapy into phase 3 and more... |
| 2022-11-23 00:15 | | The return of rep access: Report suggests bounce-back in rate of pharma-friendly docs and more... |
| 2022-11-22 12:15 | | GSK to pull blood cancer drug from US market after study failure and more... |
| 2022-11-22 00:15 | | NW Bio reports positive top-line results from phase 3 glioblastoma trial and more... |
| 2022-11-21 12:15 | | Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis and more... |
| 2022-11-21 00:15 | | Lysogene's lead gene therapy flunks phase 2/3 trial almost a year after Sarepta walked out and more... |
| 2022-11-18 12:15 | | 'I would put us up against mRNA': Novavax sets out vision for vaccine success in COVID and beyond and more... |
| 2022-11-18 00:15 | | Medtronic begins U.S. launch of 7-day insulin infusion set and more... |
| 2022-11-17 12:15 | | Months removed from a $118M Series B, Mineralys pushes ahead with PhII hypertension data and more... |
| 2022-11-17 00:15 | | In surprise turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions and more... |
| 2022-11-16 12:15 | | Roche Failure Leaves Industry Reassessing Alzheimer's Space and more... |
| 2022-11-16 00:15 | | Pear Therapeutics to Undergo Another Round of Layoffs and more... |
| 2022-11-15 12:15 | | Pittsburgh Sees Transformation into Life Sciences Hotbed and more... |
| 2022-11-15 00:15 | | Paper reopens debate over drug sampling and more... |
| 2022-11-14 12:15 | | Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers and more... |
| 2022-11-14 00:15 | | Autoimmune Biotech Zenas Gets $118M to Take Antibody Drug Into Phase 3 and more... |
| 2022-11-11 12:15 | | AZ claims another Imjudo approval, in big first-line NSCLC market and more... |
| 2022-11-11 00:15 | | 'The decision is clear': Curis cuts workforce as pending data hint at near-term FDA application and more... |
| 2022-11-10 12:15 | | Biogen appoints ex-Sanofi chief Christopher Viehbacher as CEO and more... |
| 2022-11-10 00:15 | | Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3 and more... |
| 2022-11-09 12:15 | | Biotechs put assets up for sale and on the shelf in quarterly pipeline clear-outs and more... |
| 2022-11-09 00:15 | | J&J vet Mammen wanted board influence to be Biogen's next CEO, but chairman said no and more... |
| 2022-11-08 12:15 | | Pharmacists, public health officials report nationwide amoxicillin shortage and more... |
| 2022-11-08 00:15 | | Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers and more... |
| 2022-11-07 12:15 | | Amgen to test new way to lower heart risk with large drug trial and more... |
| 2022-11-07 00:15 | | Eli Lilly, Boehringer Ingelheim bolster case for Jardiance to treat chronic kidney disease and more... |
| 2022-11-04 12:15 | | Roche introduces the navify brand for its digital health solutions at HLTH 2022 and more... |
| 2022-11-04 00:15 | | Exelixis Inks Third Collaboration Deal in a Week, This Time with Catalent and more... |
| 2022-11-03 12:15 | | Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod and more... |
| 2022-11-03 00:15 | | Rubius’s New Cell Therapy Strategy Runs Out of Time & Money; Workforce Is Cut by 82% and more... |
| 2022-11-02 12:15 | | After Haleon spinoff, GSK raises forecasts on ‘strong’ Q3 and more... |
| 2022-11-02 00:15 | | Lilly sales of new diabetes drug accelerate on rising patient demand and more... |
| 2022-11-01 12:15 | | ASN to Spotlight Debate around Ardelyx's Embattled CKD Drug and more... |
| 2022-11-01 00:15 | | AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others and more... |
